Results: radioactive labelled endothelin-1 and endothelin-B receptor binding was reduced in varicose compared to control veins (p=0.04). Endothelin-A receptor binding was diffuse, with no difference in density in both groups (p=0.58). Endothelin-B receptor binding was diffuse with superimposed clusters. Although the density of medial endothelin-B receptor binding was reduced in the varicose group, more clusters were identified in this group compared to controls (p=0.005). CD-31 staining identified these clusters as endothelial cells.
Introduction
a potent smooth muscle mitogen and stimulus for endothelial cell migration, proliferation and angiogenesis. 11, 12 It is produced and released from the endoVaricose veins are the commonest feature of chronic thelium in response to several factors including venous disease affecting 10-45% of the adult popuincreased mechanical stress and the presence of thromlation in Western societies.
1,2 The primary cause of bin, both of which are present in venous hypertension venodilatation, poor contractility and recurrence foland varicose veins. 13, 14 Systemic levels of ET-1 and ETlowing treatment of varicose veins remains unclear. 3 1 receptor affinity have been reported as unchanged The aetiology, diagnosis and treatment are often exin patients with varicose veins. 15 We hypothesise that plained on the basis of the existence of valvular inthe density, distribution and function of these ensufficiency.
dothelin receptors may contribute to the pathogenesis The primary aetiology of lower limb varicosis may of varicose veins. however lie in the inherent venous wall weakness
In addition, studies on recurrent varicose veins, as shown by smooth muscle malfunction and which occur in 20-30% of cases following surgery, abnormalities of the connective tissue collagen and have suggested a role for neovascularisation in the elastin structure and content. [4] [5] [6] [7] Smooth muscle mainaetiology of varicose veins. 8, 9 Venous tissue blocks tenance of venous tone is implemented in part by the excised from 28 legs undergoing groin re-exploration local effect of endogenous vasoconstrictor agents, of for recurrence showed evidence of neovascularisation which endothelin (ET-1) is the most potent. 10 This in 27 groins with the latter as the sole cause of reendothelium derived 21-amino acid peptide is also currence in 19 (68%) groins. 8 Biotech) in X-ray cassettes for up to 4 days at 4°C. Films were then processed according to the manufacturer's Venous tissue from nine patients (five males and four instructions. Binding sites were localised at the cellular females, aged 54±5 years) undergoing primary var-level by dipping incubated sections in molten nuclear icose vein surgery was obtained. Clinically three emulsion (K2 emulsion, Ilford, Moberley, Cheshire, patients had venous disease with skin damage (severe, U.K.) and exposing for up to 8 days in lightproof C4), two had varicose veins with venous oedema boxes at 4°C. Emulsion was then processed and tissue (moderate, C3) and four had gross varicosis with stained with Mayer's haematoxylin and eosin for hisneither oedema nor skin damage (mild, C2). Although tology. duplex ultrasound confirmation of long saphenous incompetence was obtained in the patients, selection was based on the clinical evidence of overt varicose Quantification of binding veins. Tissue from six patients (four males and two females, aged 58±4 years) with no evidence of venous Receptor binding was assessed and quantified by disease and undergoing coronary artery bypass graft-densitometry using a GS 700 Imager and Densitometer ing using autologous saphenous vein was obtained as (BioRAD Laboratories, Hercules, California, U.S.A.). controls. Patients were informed of the procedure and Binding was calculated based on standard curves genconsent obtained.
erated by 125 I microscales. Specific receptor binding was calculated by subtracting non-specific from total binding.
Endothelial cells were identified by immunoTissue collection histochemistry using Vector's avidin-biotin complex method (ABC Vector Laboratories, Petersborough, The proximal 2 cm of the long saphenous vein was U.K.). Details of the protocol are as previously taken after ligation and division at the saphenofemoral described. 16 Platelet endothelial adhesion molecule-1 junction. Utmost care was taken in the handling of the (PECAM, CD31) antibody for endothelial cells vein and crushed ends at ligation excised with a sharp (1:1000 dilution, DAKO Ltd, High Wycombe, Buckblade. Samples were snap frozen in isopentane/liquid inghamshire, U.K.) was used to identify the endothelial nitrogen and stored at −80°C.
cells within the vein sections. ET-1 immunoreactivity was also identified in a limited number of control and varicose vein sections using an anti-ET-1 monoclonal antibody (Peninsula Labs, CA, U.S.A., diluted 1:500). In-vitro autoradiography Endothelin receptors were identified as previously described. 16 Briefly, slide-mounted vein sections were Cell counts pre-incubated in 50 mmol/L tris HCl buffer, pH 7.4, for 15 min at 22°C in order to reduce endogenous Microscopic images of vein sections were transferred onto a monitor via a CCD camera attachment on an peptide levels. Binding was determined by incubating Olympus BX50 microscope. ET B clusters and CD31 positive endothelial cells/sites were counted using a 500×500 m grid at ×100-magnification and standardised to counts per section.
Results were analysed using Microsoft Excel 97 (Microsoft Inc., Washington DC, U.S.A.) and Graphpad Prism for Windows statistical packages. Densitometry was performed on four sections per subject expressed as mean (confidence intervals) in the text. The final reading for each patient was the mean total ET-1 binding minus non-specific ET-1 binding for four adjacent vein sections. The results obtained were then compared using Student's unpaired t-test. A p-value <0.05 was considered significant. The CD31 and CD31 ET B counts were per section and compared using Mann-Whitney U-test.
Results
There was demonstrable ET-1 binding which was associated with both ET A and ET B receptors in all the sections studied. Macroscopically, all three radioligands bound to the smooth muscle of the venous tunica media. Non-specific binding, in the presence of a saturating concentration of unlabelled ET-1 (1 mol/ L) accounted for 0-15% of total binding (specific binding therefore 85-100% total binding).
Results and ET-1. ET-1 is a 21 amino acid peptide with a short agents -norepinephrine, angiotensin and endothelin. 21 Of these vasoactive agents, endothelin is the most plasma half-life. 22 Since ET-1 was first isolated from porcine endothelial cells in 1988, 11 it has been impotent. This discussion is based on the two main findings in our study. Firstly, the diminished medial plicated in a host of cardiovascular diseases and pathologies involving altered smooth muscle contractility endothelin binding and receptor density in varicose veins, which may in part account for the poor con-in tubular organs. 12, 16, 22 Its action is likely to be at local tissue level rather than systemic. ET-1 induced tractile response in these vessels. Secondly, the marked increase in ET B receptor binding to endothelial cells vasocontractility is mediated via both ET A and ET B receptor subtypes. 23 The presence of both receptor in the varicose vein wall, which we speculate, may mediate neovascularisation as a potential cause of subtypes has been demonstrated in human long saphenous vein. 24 Contractions to ET-1 are diminished varicose veins.
The maintenance of venous tone is dependent on in varicose veins compared to control veins. 21 Further studies have shown similar plasma levels of ET-1 and the action of the sympathetic nervous system and 25 Decreased binding and receptor availability may partly account for the impaired tone and contractility in varicose veins. Whether this is the primary insult or the result of disease progression is unclear at this stage.
Varicose veins have been shown to have a higher blood flow rate and increased blood oxygenation than non-varicose veins. 26, 27 These observations have been associated with the often quoted but rather debatable arteriovenous fistulae theory in the aetiology of varicose veins. [28] [29] [30] Experimental arteriovenous fistulae in canine veins have been shown to be associated with and a reduced maximal contractility response to ET-1. 32 Although these studies are yet to be confirmed in humans, we speculate that the chronic exposure of varicose veins to high flow, stress or oxygenation may similar ET receptor affinities in varicose and nonbe contributory to the desensitisation or reduction in varicose veins. 15 Our study demonstrated a reduced ET receptors as shown by our study. density of ET-1 binding and ET B receptor subtypes
In addition to its effect on vascular tone, ET-1 has in varicose veins and suggests a fundamental local been shown to have mitogenic and angiogenic propreduction in receptor availability (Fig. 2) . These finderties. [33] [34] [35] ET-1 is produced by endothelial cells. Growth ings are in keeping with similar studies on pulverised and migration of endothelial cells control the vascular veins. 15 Whether the reduced contractility is due remodelling that is necessary for healing and is asto desensitisation, internalisation, degenerative or sociated with various vascular diseases. Morbidelli et genetically determined lowering in absolute receptor numbers is unclear. Although our study was limited al. have shown that ET-1 stimulates endothelial cell 36 This autocrine effect is mediated via potential cause of primary and recurrent varicose ET B receptors. Our study showed a reduction in ET B veins. receptor binding to the tunica media in the varicose vein group, whereas there was discrete clustering of ET B receptors in this region (Figs 3 and 4) . Initially, it was thought that these clusters might represent bindReferences ing to vasa vasorum as previously reported in coronary arteries 16 leading to the possibility of altered blood histochemistry, however, revealed that these clusters 167-173. were collections of endothelial cells within the media. 
